West Pharmaceutical Services (WST)
Supplies injectable-drug containment, delivery systems, and contract device manufacturing.
Something off on this page? Send us feedback.
Sells stoppers, seals, syringe and cartridge components, polymer containment, self-injection systems, and analytical services for injectable drugs, while West Vantage designs and manufactures complex healthcare devices for customers. Proprietary Products supplies most revenue, with regulated quality systems and global production shaping the business.
Supplies injectable-drug containment and delivery through Proprietary Products, its larger segment. The portfolio includes elastomer stoppers and seals, syringe and cartridge components, polymer vials and syringes, reconstitution and transfer systems, self-injection devices, analytical lab services, and packaging support for biologic, generic, and pharmaceutical customers.
West Vantage designs, molds, assembles, and packages customer-owned complex devices and combination products for pharmaceutical, diagnostic, and medical-device customers. Manufacturing spans the Americas, Europe, and Asia, with more than half of sales generated outside the United States.
Competes through container-closure expertise, regulatory quality, technical support, and the ability to make products at multiple sites. Sales are concentrated among major drugmakers; production depends on regulated processes and single-source suppliers for some critical materials.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Morgan Stanley | Upgrade | Target: $365 | Target: $400 |
| Sep 9, 2026 | UBS | Reiterate | Rating: —Target: $340 | Target: $415 |
| Jul 27, 2026 | Evercore ISI | Reiterate | Rating: —Target: $410 | Target: $425 |
| Jul 13, 2026 | Exane BNP Paribas | Initiate | Rating: — | |
| Jul 13, 2026 | BNP Paribas | Target | Target: — | Target: $447 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $435.8M · Total debt $312.1M · Total assets $4.08B · Shareholders' equity $2.99B
- Revenue
- $872.3M
- Operating income
- $179.1M
- Net income
- $154.0M
HistoryDividendAnnual yield
| Institutions | ≈ 100.70% | 70.87M shares | |
|---|---|---|---|
| 853 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.65% | 460.8K shares | |
| 23 holders · as of Sep 15, 2026 | |||
| Strategic holders | 6.82% | 4.80M shares | |
| 1 holder · as of Jan 28, 2019 | |||
| Adds to | 108.17% | ||
70.38M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 108.17%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.45% | 6.65M | as of Jun 30, 2026 |
Franklin Resources, Inc.Strategic | 6.82% | 4.80M | filed Jan 28, 2019 |
Vanguard Capital Management LLCInstitution | 6.56% | 4.61M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.71% | 4.02M | as of Jun 30, 2026 |
FMR LLCInstitution | 5.08% | 3.57M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Annette F. Favorite | officer: Sr. VP & Chief HR Officer | −2,524 | $365.00 |
| Sep 14, 2026 | Annette F. Favorite | officer: Sr. VP & Chief HR Officer | −2,500 | $355.00 |
| Sep 11, 2026 | Annette F. Favorite | officer: Sr. VP & Chief HR Officer | −2,500 | $345.00 |
| Sep 8, 2026 | Annette F. Favorite | officer: Sr. VP & Chief HR Officer | −2,500 | $340.81 |
| Apr 27, 2026 | Chad Winters | officer: VP, Chief Accounting Officer | −896 | $300.67 |
- AptarGroup
Injectable elastomers and pharma delivery services overlap core containment
- Stevanato Group
High-value syringes, vials, and device manufacturing overlap biologics
- BD
Prefillable syringes and self-injection systems challenge delivery devices
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| West Pharmaceutical Services | $372.07 | +2.84% | $25.46B | 46.3 | 40.2 | 7.7 | +13.9% |
| AptarGroup | $125.41 | +1.63% | $7.88B | 22.3 | 21.1 | 2.0 | +6.3% |
| Stevanato Group | $21.68 | +0.79% | $5.87B | 39.1 | 27.8 | 4.2 | +4.6% |
| BD | $181.60 | +0.50% | $49.79B | 54.4 | 13.7 | 2.4 | −9.6% |
| Median | 39.1 | 21.1 | 2.4 | +4.6% |